Article Corrected

Hoy SM, Keating GM. Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. Drugs 2012; 72 (5): 643-69

Corrections Made

Page 650, table III, TEMPO study, column 3: The final column (PL) was missing from this table and has now been added:

Table III
figure Tab1

Table III. Features of randomized, double-blind, multinational studies in patients with early Parkinson’s disease

Full size image

Page 644, abstract, paragraph 1, lines 3 and 4: The following sentence, which previously read:

It is indicated as monotherapy or as adjunctive therapy to levodopa for the treatment of idiopathic Parkinson’s disease in adult patients with end-of-dose fluctuations in the EU and for the treatment of adult patient with the signs and symptoms of idiopathic Parkinson’s disease in the US.

has now been corrected as follows:

It is indicated for the treatment of idiopathic Parkinson’s disease as monotherapy or as adjunctive therapy to levodopa in patients with end-of-dose fluctuations in the EU and for the treatment of adult patients with the signs and symptoms of idiopathic Parkinson’s disease in the US.

Page 662, column 2, section 7, paragraph 2, lines 1–4: The following sentence, which previously read:

In the EU,[10] oral rasagiline is indicated as monotherapy or as adjunctive therapy to levodopa for the treatment of idiopathic Parkinson’s disease in adult patients with end-of-dose fluctuations.

has now been corrected as follows:

In the EU,[10] oral rasagiline is indicated for the treatment of idiopathic Parkinson’s disease as monotherapy or as adjunctive therapy to levodopa in patients with end-of-dose fluctuations.

Note

All versions of this article have been updated to reflect these corrections.